EXHIBIT
10.1
SECURITIES PURCHASE
AGREEMENT
This Securities Purchase Agreement
(this “ Agreement ”) is dated as of October 6,
2009 among Zurvita Holdings, Inc., a Delaware (the “
Company ”), and Vicis Capital Master Fund (the
“Purchaser”).
WHEREAS, subject to the terms and
conditions set forth in this Agreement and pursuant to Section 4(2)
of the Securities Act of 1933, as amended (the “
Securities Act ”) and Rule 506 promulgated thereunder,
the Company desires to issue and sell to Purchaser, and Purchaser
desires to purchase from the Company, securities of the Company as
more fully described in this Agreement.
NOW, THEREFORE, IN CONSIDERATION of
the mutual covenants contained in this Agreement, and for other
good and valuable consideration the receipt and adequacy of which
are hereby acknowledged, the Company and Purchaser agree as
follows:
ARTICLE I
DEFINITIONS
1.1 Definitions
. In addition to the terms defined elsewhere in this
Agreement: (a) capitalized terms that are not otherwise defined
herein have the meanings given to such terms in the Series B
Designations (as defined herein), and (b) the following terms have
the meanings indicated in this Section 1.1 :
“ Affiliate ”
means any Person that, directly or indirectly through one (1) or
more intermediaries, controls or is controlled by or is under
common control with a Person, as such terms are used in and
construed under Rule 144 under the Securities Act. With
respect to a Purchaser, any investment fund or managed account that
is managed on a discretionary basis by the same investment manager
as such Purchaser will be deemed to be an Affiliate of such
Purchaser.
“ Business Day ”
means any day except Saturday, Sunday, any day which shall be a
federal legal holiday in the United States or any day on which
banking institutions in the State of New York are authorized or
required by law or other governmental action to close.
“ Closing ” means
the closing of the purchase and sale of the Securities pursuant to
Section 2.1 .
“ Closing Date ”
means the Trading Day when all of the Transaction Documents have
been executed and delivered by the applicable parties thereto, and
all conditions precedent to (i) the Purchaser’s obligations
to pay the Subscription Amount and (ii) the Company’s
obligations to deliver the Securities have been satisfied or
waived.
“ Commission ”
means the U.S. Securities and Exchange Commission.
“ Common Stock ”
means the common stock of the Company, par value $.0001 per share,
and any other class of securities into which such securities may
hereafter be reclassified or changed into.
“ Common Stock
Equivalents ” means any securities of the Company or the
Subsidiaries which would entitle the holder thereof to acquire at
any time Common Stock, including, without limitation, any debt,
preferred stock, rights, options, warrants or other instrument that
is at any time convertible into or exercisable or exchangeable for,
or otherwise entitles the holder thereof to receive, Common
Stock.
“ Disclosure Schedules
” shall have the meaning ascribed to such term in Section
3.1.
“ Escrow Agent ”
means Sichenzia Ross Friedman Ference LLP, with offices located at
61 Broadway, New York, New York 10006.
“ Escrow Agreement
” means the escrow agreement entered into prior to
the date hereof, by and among the Company, the Purchaser and the
Escrow Agent pursuant to which the Purchaser, shall deposit the
Purchase Price with the Escrow Agent to be applied to the
transactions contemplated hereunder.
“ Exchange Act ”
means the Securities Exchange Act of 1934, as amended, and the
rules and regulations promulgated thereunder.
“ Exempt Issuance
” means: (a) shares of Common Stock or options to purchase
Common Stock issued to employees, officers, directors or
consultants of the Company pursuant to any stock or option plan
duly adopted by a majority of the non-employee members of the Board
of Directors of the Company or a majority of the members of a
committee of non-employee directors established for such purpose,
(b) securities issued upon the exercise or exchange of or
conversion of any Securities issued hereunder and/or other
securities (including the stock rights set forth on Schedule
3.1(g) ) exercisable or exchangeable for or convertible into
shares of Common Stock issued and outstanding on the date of this
Agreement, provided that, unless set forth on Schedule
3.1(g) , such securities have not been amended since the date
of this Agreement to increase the number of such securities or to
decrease the exercise, exchange or conversion price of any such
securities and (c) securities issued pursuant to acquisitions or
strategic transactions approved by a majority of the directors,
provided that any such issuance shall only be to a Person which is,
itself or through its subsidiaries, an operating company in a
business synergistic with the business of the Company, as
determined by a majority of the directors, and in which the Company
receives benefits in addition to the investment of funds, but shall
not include a transaction in which the Company is issuing
securities primarily for the purpose of raising capital or to an
entity whose primary business is investing in
securities.
“ Liens ” means a
lien, charge, security interest, encumbrance, right of first
refusal, preemptive right or other restriction.
“ Material Adverse
Effect ” shall have the meaning assigned to such term in
Section 3.1(b).
“ Person ” means
an individual or corporation, partnership, trust, incorporated or
unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or
subdivision thereof) or other entity of any kind.
“ Proceeding ”
means an action, claim, suit, investigation or proceeding
(including, without limitation, an investigation or partial
proceeding, such as a deposition), whether commenced or
threatened.
“ Public Information
Failure ” shall have the meaning ascribed to such term in
Section 4.14 (b).
“ Public Information
Failure Payments ” shall have the meaning ascribed to
such term in Section 4.14(b).
“ Required Approvals
” shall have the meaning ascribed to such term in Section
3.1(e).
“ Required Minimum
” means, as of any date, one hundred and ten percent (110%)
of the maximum aggregate number of shares of Common Stock then
issued or potentially issuable in the future pursuant to the
Transaction Documents, including any Underlying Shares issuable
upon exercise or conversion in full of all Series B Warrants and
Series B Convertible Preferred Stock (including a reasonable
reserve for Underlying Shares issuable as payment of dividends),
ignoring any conversion or exercise limits set forth
therein.
“ Rule 144” means
Rule 144 promulgated by the Commission pursuant to the Securities
Act, as such rule may be amended from time to time, or any similar
rule or regulation hereafter adopted by the Commission having
substantially the same effect as such Rule.
“ Securities ”
means the Series B Convertible Preferred Stock, the Series B
Warrants, the Warrant Shares and the Underlying Shares.
“ Securities Act
” means the Securities Act of 1933, as amended, and the rules
and regulations promulgated hereunder.
“ Series B Convertible
Preferred Stock ” means the Series B Convertible
Preferred Stock of the Company and such designations, preferences
and limitations as are set forth in the Series B
Designations.
“ Series B Designations
” means the Certificate of Designation, Preferences and
Rights of Series B Convertible Preferred Stock filed with the State
of Delaware on October 6, 2009.
“ Series B Warrant
” means the Series B Common Stock Purchase Warrant, in the
form of Exhibit A attached hereto, delivered to the
Purchaser at the Closing in accordance with Section
2.2(a)(v) hereof.
“ Short Sales ”
shall include all “short sales” as defined in Rule 200
of Regulation SHO under the Exchange Act (but shall not be deemed
to include the location and/or reservation of borrowable shares of
Common Stock).
“ Subsidiary ”
means any subsidiary of the Company as set forth on Schedule
3.1(a) .
“ Super 8-K
” means the Current Report on Form 8-K delivered
to Purchaser prior to the date hereof and to be filed by the
Company within four Business Days of the Closing date, along with
the exhibits filed in connection therewith.
“ Trading Day ”
means a day on which the Common Stock is traded on a Trading
Market.
“ Trading Market
” means the following markets or exchanges on which the
Common Stock is listed or quoted for trading on the date in
question: the Nasdaq Capital Market, the NYSE Amex, the New York
Stock Exchange, the Nasdaq National Market, the OTC Bulletin Board,
or “Pink Sheets” published by Pink Sheets, LLC (or a
similar organization or agency succeeding to its functions of
reporting prices).
“ Transaction Documents
” means this Agreement, the Series B Designations, the Series
B Warrants, the Escrow Agreement and any other documents or
agreements executed in connection with the transactions
contemplated hereunder.
“ Underlying Shares
” means the shares of Common Stock issued and issuable upon
conversion or redemption of the Series B Convertible Preferred
Stock and upon exercise of the Series B Warrants.
“ VWAP ” of a
share of Common Stock as of a particular date (the
“Determination Date”) shall mean the price determined
by the first of the following clauses that applies: (a) if shares
of Common Stock are traded on a national securities exchange (an
“Exchange”), the weighted average of the closing sale
price of a share of the Common Stock of the Company on the last
five (5) Trading Days prior to the Determination Date reported on
such Exchange as reported in The Wall Street Journal (weighted with
respect to the trading volume with respect to each such day); (b)
if shares of Common Stock are not traded on an Exchange but trade
in the over-the-counter market and such shares are quoted on the
National Association of Securities Dealers Automated Quotations
System (“NASDAQ”), the weighted average of the closing
sale price of a share of the Common Stock of the Company on the
last five (5) Trading Days prior to the Determination Date reported
on NASDAQ as reported in The Wall Street Journal (weighted with
respect to the trading volume with respect to each such day); (c)
if such shares are an issue for which last sale prices are not
reported on NASDAQ, the average of the closing sale price, in each
case on the last five (5) Trading Days (or if the relevant price or
quotation did not exist on any of such days, the relevant price
or
quotation on the next preceding Business Day on
which there was such a price or quotation) prior to the
Determination Date as reported by the Over the Counter Bulletin
Board (the “OTCBB”), or any other successor
organization; (d) if no closing sales price is reported for the
Common Stock by the OTCBB or any other successor organization for
such day, the average of the closing sale price, in each case on
the last five (5) Trading Days (or if the relevant price or
quotation did not exist on any of such days, the relevant price or
quotation on the next preceding business day on which there was
such a price or quotation) prior to the Determination Date as
reported by the "pink sheets" by the Pink Sheets, LLC,
or any successor organization, (e) if no closing sales price is
reported for the Common Stock by the OTCBB or any other successor
organization for such day, then the average of the high and low bid
and asked price of any of the market makers for the Common Stock as
reported on the OTCBB or in the “pink sheets” by the
Pink Sheets, LLC on the last five (5) Trading Days; or (e) in all
other cases, the fair market value of a share of Common Stock as
determined by an independent appraiser selected in good faith by
the holder and reasonably acceptable to the Company.
“ Warrant Shares
” means the shares of Common Stock issuable upon exercise of
the Series B Warrants.
ARTICLE II
PURCHASE AND SALE
2.1 Closing
. On the Closing Date, upon the terms and subject to the
conditions set forth herein, concurrent with the execution and
delivery of this Agreement by the parties hereto, the Purchaser
agrees to purchase, and the Company agrees to sell 2,000,000 shares
of Series B Convertible Preferred Stock, each share having a Stated
Value of $1.00, along with the Series B Warrants (as referred to in
Section 2.2(a)(iii) below) for an aggregate purchase price
of $2,000,000 (the “ Purchase Price
”). On the Closing Date, subject to the terms of
this Agreement, Purchaser shall cause the Purchase Price to be
delivered to the Company via wire transfer or a certified check in
immediately available funds and the Company shall deliver to the
Purchaser the Series B Convertible Preferred Stock and the Series B
Warrants and the other items set forth in Section 2.2
issuable at the Closing. Upon satisfaction of the
conditions set forth in Sections 2.2 and 2.3 , the
Closing shall occur at the offices of Sichenzia Ross Friedman
Ference LLP, 61 Broadway, New York 10006, or such other location as
the parties shall mutually agree.
2.2 Deliveries
.
(a) On the Closing
Date, the Company shall deliver or cause to be delivered to the
Purchaser the following:
(i) this Agreement
duly executed by the Company;
(ii) a certificate
evidencing 2,000,000 shares of Series B Convertible Preferred
Stock;
(iii) a Series B
Warrant, in the name of the Purchaser, to purchase 8,000,000 shares
of Common Stock, with an exercise price equal to Twenty-Five Cents
($0.25), subject to adjustment therein, with a term of exercise of
seven (7) years;
(iv) any required
consents or waivers;
(v) an officer’s
certificate and secretary’s certificate in form and substance
reasonably acceptable to the Purchaser;
(vi) the Escrow
Agreement duly executed by the Company;
(vii) the Release Notice
(as defined in the Escrow Agreement) duly executed by the Company;
and
(b) On or prior to the
Closing Date, the Purchaser shall deliver or cause to be delivered
to the Company the following:
(i) this
Agreement duly executed by such Purchaser;
(ii) the Escrow
Agreement duly executed by the Purchaser;
(iii) the Release Notice
(as defined in the Escrow Agreement) for the delivery of the
Purchase Price duly executed by the Purchaser.
2.3 Closing
Conditions .
(a) The obligations of
the Company hereunder in connection with the Closing are subject to
the following conditions being met:
(i) the
accuracy in all material respects when made and on the Closing Date
of the representations and warranties of the Purchaser contained
herein;
(ii) all obligations,
covenants and agreements of the Purchaser required to be performed
at or prior to the Closing Date shall have been performed;
and
(iii) the delivery by
the Purchaser of the items set forth in Section 2.2(b) of
this Agreement.
(b) The obligations of
the Purchaser hereunder in connection with the Closing are subject
to the following conditions being met:
(i) the
accuracy in all material respects on the Closing Date of the
representations and warranties of the Company contained
herein;
(ii) all obligations,
covenants and agreements of the Company required to be performed at
or prior to the Closing Date shall have been performed;
(iii) the delivery by
the Company of the items set forth in Section 2.2(a) of this
Agreement; and
(iv) there shall have
been no Material Adverse Effect with respect to the Company since
the date of the balance sheet included in the Super 8-K (the
“Balance Sheet”).
ARTICLE III
REPRESENTATIONS AND
WARRANTIES
3.1 Representations
and Warranties of the Company . Except as set forth
under the corresponding section of the disclosure schedules
delivered to the Purchaser concurrently herewith (the “
Disclosure Schedules ”) which Disclosure Schedules
shall be deemed a part hereof and to qualify any representation or
warranty otherwise made herein to the extent of such disclosure,
the Company hereby makes the representations and warranties set
forth below to Purchaser.
(a)
Subsidiaries . All of the direct and indirect
subsidiaries of the Company are set forth on Schedule 3.1(a)
. The Company owns, directly or indirectly, all of the
capital stock or other equity interests of each Subsidiary free and
clear of any Liens, and all the issued and outstanding shares of
capital stock of each Subsidiary are validly issued and are fully
paid, non-assessable and free of preemptive and similar rights to
subscribe for or purchase securities. If the Company has
no Subsidiaries, then all other references in the Transaction
Documents to the Subsidiaries or any of them will be
disregarded.
(b) Organization
and Qualification . The Company and each of the
Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the
jurisdiction of its incorporation or organization (as applicable),
with the requisite corporate power and authority to own and use its
properties and assets and to carry on its business as currently
conducted. Neither the Company nor any Subsidiary is in
violation or default of any of the provisions of its respective
certificate or articles of incorporation, bylaws or other
organizational or charter documents. The Company and
each of the Subsidiaries is duly qualified to conduct business and
is in good standing as a foreign corporation or other entity in
each jurisdiction in which the nature of the business conducted or
property owned by it makes such qualification necessary, except
where the failure to be so qualified or in good standing, as the
case may be, could not have or reasonably be expected to result in
(i) a material adverse effect on the legality, validity or
enforceability of any Transaction Document, (ii) a material adverse
effect on the results of operations, assets, business, prospects or
condition (financial or otherwise) of the Company and the
Subsidiaries, taken as a whole, or (iii) a material adverse effect
on the Company’s ability to perform in any material respect
on a timely basis its obligations under any Transaction Document
(any of (i), (ii) or (iii), a “ Material Adverse
Effect ”) and no Proceeding has been instituted in any
such jurisdiction revoking, limiting or curtailing or seeking to
revoke, limit or curtail such corporate power and authority or
qualification.
(c) Authorization;
Enforcement . The Company has the requisite
corporate power and authority to enter into and to consummate the
transactions contemplated by each of the Transaction Documents and
otherwise to carry out its obligations hereunder and
thereunder. The execution and delivery of each of the
Transaction Documents by the Company and the consummation by it of
the transactions contemplated hereby and thereby have been duly
authorized by all necessary corporate action on the part of the
Company and no further action is required by the Company, its board
of directors or its stockholders in connection therewith other than
in connection with the Required Approvals. Each
Transaction Document has been (or upon delivery will have been)
duly executed by the Company and, when delivered in accordance with
the terms hereof and thereof, will constitute the valid and binding
obligation of the Company enforceable against the Company in
accordance with its terms except (i) as limited by general
equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application
affecting enforcement of creditors’ rights generally, (ii) as
limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and
(iii) insofar as indemnification and contribution provisions may be
limited by applicable law.
(d) No
Conflicts . The execution, delivery and performance
of the Transaction Documents by the Company and the consummation by
the Company of the other transactions contemplated hereby and
thereby do not and will not: (i) conflict with or violate any
provision of the Company’s or any Subsidiary’s
certificate or articles of incorporation, bylaws or other
organizational or charter documents, or (ii) conflict with, or
constitute a default (or an event that with notice or lapse of time
or both would become a default) under, result in the creation of
any Lien upon any of the properties or assets of the Company or any
Subsidiary, or give to others any rights of termination, amendment,
acceleration or cancellation (with or without notice, lapse of time
or both) of, any agreement, credit facility, debt or other
instrument (evidencing a Company or Subsidiary debt or otherwise)
or other understanding to which the Company or any Subsidiary is a
party or by which any property or asset of the Company or any
Subsidiary is bound or affected, or (iii) subject to the Required
Approvals, conflict with or result in a violation of any law, rule,
regulation, order, judgment, injunction, decree or other
restriction of any court or governmental authority to which the
Company or a Subsidiary is subject (including federal and state
securities laws and regulations), or by which any property or asset
of the Company or a Subsidiary is bound or affected; except in the
case of each of clauses (ii) and (iii), such as could not have or
reasonably be expected to result in a Material Adverse
Effect.
(e) Filings,
Consents and Approvals . The Company is not required
to obtain any consent, waiver, authorization or order of, give any
notice to, or make any filing or registration with, any court or
other federal, state, local or other governmental authority or
other Person in connection with the execution, delivery and
performance by the Company of the Transaction Documents, other than
the filing of Form D with the Commission and such filings as are
required to be made under applicable state securities
laws (the “ Required Approvals
”).
(f) Issuance of the
Securities . The Securities are duly authorized and,
when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid
and nonassessable, free and clear of all Liens imposed by the
Company other than restrictions on transfer provided for in the
Transaction Documents. The Underlying Shares, when
issued in accordance with the terms of the Transaction Documents,
will be validly issued, fully paid and nonassessable, free and
clear of all Liens imposed by the Company. The Company
has reserved from its duly authorized capital stock a number of
shares of Common Stock for issuance of the Underlying Shares at
least equal to the Required Minimum on the date hereof.
(g)
Capitalization . The capitalization of the
Company is as set forth on Schedule 3.1(g)
. Except as set forth on Schedule 3.1(g), no Person has
any right of first refusal, preemptive right, right of
participation, or any similar right to participate in the
transactions contemplated by the Transaction
Documents. Except as a result of the purchase and sale
of the Securities and as set forth on Schedule 3.1(g) ,
there are no outstanding options, warrants, script rights to
subscribe to, calls or commitments of any character whatsoever
relating to, or securities, rights or obligations convertible into
or exercisable or exchangeable for, or giving any Person any right
to subscribe for or acquire, any shares of Common Stock, or
contracts, commitments, understandings or arrangements by which the
Company or any Subsidiary is or may become bound to issue
additional shares of Common Stock or Common Stock
Equivalents. The issuance and sale of the Securities
will not obligate the Company to issue shares of Common Stock or
other securities to any Person (other than the Purchaser) and will
not result in a right of any holder of Company securities to adjust
the exercise, conversion, exchange or reset price under any of such
securities. All of the outstanding shares of capital
stock of the Company are validly issued, fully paid and
nonassessable, have been issued in compliance with all federal and
state securities laws, and none of such outstanding shares was
issued in violation of any preemptive rights or similar rights to
subscribe for or purchase securities. No further
approval or authorization of any stockholder, the Board of
Directors of the Company or others is required for the issuance and
sale of the Securities. There are no stockholders
agreements, voting agreements or other similar agreements with
respect to the Company’s capital stock to which the Company
is a party or, to the knowledge of the Company, between or among
any of the Company’s stockholders.
(h) Financial
Statements . The financial statements of the Company
included in the Super 8-K and provided to the Purchaser comply in
all material respects with the applicable accounting requirements
and the rules and regulations of the Commission. Such
financial statements have been prepared in accordance with United
States generally accepted accounting principles applied on a
consistent basis during the periods involved (“GAAP”),
except as may be otherwise specified in such financial statements
or the notes thereto and except that unaudited financial statements
may not contain all footnotes required by GAAP, and fairly present
in all material respects the financial position of the Company and
its consolidated Subsidiaries as of and for the dates thereof and
the results of operations and cash flows for the periods then
ended, subject, in the case of unaudited statements, to normal,
immaterial, year-end audit adjustments.
(i) Material
Changes . Since the date of the latest financial
statements included within the Super 8-K, and delivered to the
Purchaser (i) there has been no event, occurrence or development
that has had or that could reasonably be expected to result in a
Material Adverse Effect, (ii) the Company has not incurred any
material liabilities (contingent or otherwise) other than (A) trade
payables and accrued expenses incurred in the ordinary course of
business consistent with past practice and (B) liabilities not
required to be reflected in the Company’s financial
statements pursuant to GAAP, (iii) the Company has not materially
altered its method of accounting, (iv) the Company has not declared
or made any dividend or distribution of cash or other property to
its stockholders or purchased, redeemed or made any agreements to
purchase or redeem any shares of its capital stock and (v) the
Company has not issued any equity securities to any officer,
director or Affiliate, except pursuant to existing Company stock
option or stock grant plans.
(j) Litigation
. Except as set forth on Schedule 3.1(j) , there
is no action, suit, inquiry, notice of violation, proceeding or
investigation pending or, to the knowledge of the Company,
threatened against or affecting the Company, any Subsidiary or any
of their respective properties before or by any court, arbitrator,
governmental or administrative agency or regulatory authority
(federal, state, county, local or foreign) (collectively, an
“ Action ”) which (i) adversely affects or
challenges the legality, validity or enforceability of any of the
Transaction Documents or the Securities or (ii) could, if there
were an unfavorable decision, have or reasonably be expected to
result in a Material Adverse Effect. Neither the Company
nor any Subsidiary, nor, to the best of the knowledge of the
Company, any director or officer thereof, is or has been the
subject of any Action involving a claim of violation of or
liability under federal or state securities laws or a claim of
breach of fiduciary duty.
(k) Labor
Relations . No material labor dispute exists or, to
the knowledge of the Company, is imminent with respect to any of
the employees of the Company or any Subsidiary which could
reasonably be expected to result in a Material Adverse Effect. None
of the Company’s or its Subsidiaries’ employees is a
member of a union that relates to such employee’s
relationship with the Company, and neither the Company nor any of
its Subsidiaries is a party to a collective bargaining agreement,
and the Company and its Subsidiaries believe that their
relationships with their employees are good. No
executive officer, to the knowledge of the Company, is, or is now
expected to be, in violation of any material term of any employment
contract, confidentiality, disclosure or proprietary information
agreement or non-competition agreement, or any other contract or
agreement or any restrictive covenant, and, to the knowledge of the
Company, the continued employment of each such executive officer
does not subject the Company or any of its Subsidiaries to any
liability with respect to any of the foregoing
matters. To the knowledge of the Company, the Company
and its Subsidiaries are in compliance with all U.S. federal,
state, local and foreign laws and regulations relating to
employment and employment practices, terms and conditions of
employment and wages and hours, except where the failure to be in
compliance could not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect.
(l) Compliance
. Neither the Company nor any Subsidiary (i) is in
material default under or in violation of (and no event has
occurred that has not been waived that, with notice or lapse of
time or both, would result in a default by the Company or any
Subsidiary under), nor has the Company or any Subsidiary received
notice of a claim that it is in default under or that it is in
violation of, any indenture, loan or credit agreement or any other
agreement or instrument to which it is a party or by which it or
any of its properties is bound (whether or not such default or
violation has been waived), (ii) is in violation of any order of
any court, arbitrator or governmental body, or (iii) to the
knowledge of the Company, is or has been in violation of any
statute, rule or regulation of any governmental authority,
including without limitation all foreign, federal, state and local
laws applicable to its business and all such laws that affect the
environment, except in each case as could not have or reasonably be
expected to result in a Material Adverse Effect.
(m) Regulatory
Permits . The Company and the Subsidiaries possess
all certificates, authorizations and permits issued by the
appropriate federal, state, local or foreign regulatory authorities
necessary to conduct their respective businesses as described in
the Super 8-K, except where the failure to possess such permits
could not have or reasonably be expected to result in a Material
Adverse Effect (“ Material Permits ”), and
neither the Company nor any Subsidiary has received any notice of
proceedings relating to the revocation or modification of any
Material Permit.
(n) Title to
Assets . The Company and the Subsidiaries have good
and marketable title in fee simple to all real property owned by
them and good and marketable title in all personal property owned
by them that is material to the business of the Company and the
Subsidiaries, in each case free and clear of all Liens, except for
Liens as do not materially affect the value of such property and do
not materially interfere with the use made and proposed to be made
of such property by the Company and the Subsidiaries, Liens for the
payment of federal, state or other taxes, the payment of which is
neither delinquent nor subject to penalties. Any real
property and facilities held under lease by the Company and the
Subsidiaries are held by them under valid, subsisting and
enforceable leases with which the Company and the Subsidiaries are
in compliance.
(o) Patents and
Trademarks . The Company and the Subsidiaries have,
or have rights to use, all patents, patent applications,
trademarks, trademark applications, service marks, trade names,
trade secrets, inventions, copyrights, licenses and other
intellectual property rights and similar rights necessary or
material for use in connection with their respective businesses as
described in the Super 8-K and which the failure to so have could
have a Material Adverse Effect (collectively, the “
Intellectual Property Rights ”). Neither
the Company nor any Subsidiary has received a notice (written or
otherwise) that the Intellectual Property Rights used by the
Company or any Subsidiary violate or infringe upon the rights of
any Person unless such notice has been resolved without a Material
Adverse Effect. To the knowledge of the Company, all such
Intellectual Property Rights are enforceable and there is no
existing infringement by another Person of any of the Intellectual
Property Rights. The Company and its Subsidiaries have
taken reasonable security measures to protect the secrecy,
confidentiality and value of all of their intellectual properties,
except where failure to do so could not, individually or in the
aggregate, reasonably be expecting to have a Material Adverse
Effect.
(p) Insurance
. Except as set forth on Schedule 3.1(p), the
Company and the Subsidiaries are insured by insurers of recognized
financial responsibility against such losses and risks and in such
amounts as are prudent and customary in the businesses in which the
Company and the Subsidiaries are engaged, including, but not
limited to, directors and officers insurance coverage at least
equal to the aggregate Subscription Amount. Neither the
Company nor any Subsidiary has any reason to believe that it will
not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar
insurers as may be necessary to continue its business without a
significant increase in cost.
(q) Transactions
With Affiliates and Employees . Excep